Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager Nanotech Investing
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference Nanotech Investing
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities Nanotech Investing
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia Nanotech Investing
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress Nanotech Investing
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers Nanotech Investing
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition Nanotech Investing
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress Nanotech Investing
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update Nanotech Investing
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference Nanotech Investing
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer Nanotech Investing
